# Motoi Suzuki, M.D., MSc. PHDC., Ph.D.

Address: Toyama 1-23-1, Shinjuku-ku, Tokyo

162-9640, JAPAN Tel: +81-3-5285-1111

E-mail: mosuzuki@niid.go.jp



### **Current position:**

- Director, Center for Surveillance, Immunization, and Epidemiologic Research, National Institute of Infectious Diseases, Tokyo, Japan
- Visiting Professor, Department of Infectious Disease Epidemiology, Tohoku University School of Medicine, Sendai
- Visiting Professor, School of Tropical Medicine and Global Health, Nagasaki University,
  Nagasaki

### **Specialities:**

Infectious disease epidemiology, Vaccine-preventable diseases

#### **Education:**

Nagasaki University Graduate School of Biomedical Sciences, Ph.D., 2014 London School of Hygiene and Tropical Medicine, MSc. of Public Health in Developing Countries, 2009

Tohoku University School of Medicine, M.D., 1996

## Positions and employment:

Positions and employment:	
Jul 2018-Mar 2019	Associate Professor, Department of Clinical Medicine,
	Institute of Tropical Medicine, Nagasaki University
Dec 2009-Jun 2018	Assistant Professor, Department of Clinical Medicine,
	Institute of Tropical Medicine, Nagasaki University
Jul 2006-Aug 2008	Assistant Professor, Vietnam Project,
	Center for International Collaborative Research, Nagasaki University,
Nha Trang, Vietnam	
Jul 2005-Jun 2006	Staff Physician, Chikamori Hospital, Kochi
Oct 2003-Apr 2005	Staff Physician, Inoue Hospital, Nagasaki
Dec 2002-Jan 2003	Staff Physician, Nagasaki University Hospital, Nagasaki
Dec 2000-Nov 2002	Staff Physician, Nijigaoka Hospital, Nagasaki
Mar 2000-Nov 2000	Staff Physician, Nomozaki Town Hospital, Nagasaki
Apr 1999-Feb 2000	Staff Physician, Nagasaki University Hospital, Nagasaki

Apr 1997-Mar 1999 Junior Resident, Katta General Hospital, Shiroishi

#### **Selected peer-reviewed publications:**

- 1. Kinoshita R, Sassa M, Otake S, et al. Impact of airline network on the global importation risk of mpox, 2022. Epidemiol Infect. 2023 Mar 21;151:e60.
- 2. Maeda H, Saito N, Igarashi A, et al. Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the SARS-CoV-2 Omicron BA.1 and BA.2 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS). Expert Rev Vaccines. 2023 Jan-Dec;22(1):288-298.
- 3. Imamura T, Watanabe A, Serizawa Y, et al. Transmission of COVID-19 in Nightlife, Household, and Health Care Settings in Tokyo, Japan, in 2020. JAMA Netw Open. 2023 Feb 1;6(2):e230589.
- 4. Arashiro T, Arai S, Kinoshita R, et al. National seroepidemiological study of COVID-19 after the initial rollout of vaccines: Before and at the peak of the Omicron-dominant period in Japan. Influenza Other Respir Viruses. 2023 Feb 1;17(2):e13094.
- 5. Kobayashi Y, Arashiro T, Otsuka M, et al. Replacement of SARS-CoV-2 strains with variants carrying N501Y and L452R mutations in Japan: an epidemiological surveillance assessment. Western Pac Surveill Response J. 2022 Sep 16;13(3):1-10.
- 6. Kayano T, Sasanami M, Kobayashi T, et al. Number of averted COVID-19 cases and deaths attributable to reduced risk in vaccinated individuals in Japan. Lancet Reg Health West Pac. 2022 Nov;28:100571.
- 7. Arashiro T, Arima Y, Muraoka H, et al. Coronavirus Disease 19 (COVID-19) Vaccine Effectiveness Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Delta-Dominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control Study (Factors Associated with SARS-CoV-2 Infection and the Effectiveness of COVID-19 Vaccines Study). Clin Infect Dis. 2023 Feb 8;76(3):e108-e115.
- 8. Hayashi K, Kayano T, Anzai A, et al. Assessing Public Health and Social Measures Against COVID-19 in Japan From March to June 2021. Front Med (Lausanne). 2022 Jul 12;9:937732.
- 9. Ko YK, Kinoshita R, Yamauchi M, et al. Impact of the Coming-of-Age Day and ceremony on the risk of SARS-CoV-2 transmission in Japan: A natural-experimental study based on national surveillance data. Influenza Other Respir Viruses. 2022 Nov;16(6):1026-1032.
- 10. Ko YK, Murayama H, Yamasaki L, et al. Age-Dependent Effects of COVID-19 Vaccine and of Healthcare Burden on COVID-19 Deaths, Tokyo, Japan. Emerg Infect Dis. 2022 Sep;28(9):1777-1784.
- 11. Arashiro T, Arima Y, Stucky A, et al. Social and Behavioral Factors Associated with Lack of Intent to Receive COVID-19 Vaccine, Japan. Emerg Infect Dis. 2022 Sep;28(9):1909-1910.
- 12. Saito N, Solante RM, Guzman FD, et al. A prospective observational study of community-acquired bacterial bloodstream infections in Metro Manila, the Philippines. PLoS Negl Trop Dis. 2022 May 25;16(5):e0010414.
- 13. Maeda H, Saito N, Igarashi A, et al. Effectiveness of Messenger RNA Coronavirus Disease 2019 Vaccines Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Delta Variant Epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS). Clin Infect Dis. 2022 Nov 30;75(11):1971-1979.
- 14. Onozuka D, Tanoue Y, Nomura S, et al. Reduced mortality during the COVID-19 outbreak in Japan, 2020: a two-stage interrupted time-series design. Int J Epidemiol. 2022 Feb 18;51(1):75-84.
- 15. Maeda H, Sando E, Toizumi M, et al. Epidemiology of Coronavirus Disease Outbreak among Crewmembers on Cruise Ship, Nagasaki City, Japan, April 2020. Emerg Infect Dis. 2021 Sep;27(9):2251-2260.